• / Free eNewsletters & Magazine
  • / My Account
Home>Investing Topics>High Yield

High Yield

  1. All
  2. Morningstar Articles
  3. Videos
  4. 3rd Party
  5. Investing
  6. Research
  1. UPDATE: This high -yield ETF is worth a close look

    UPDATE: This high - yield ETF is worth a close look

  2. Putnam Announces Distribution Rates for Open End Funds

    Putnam Announces Distribution Rates for Open End Funds

  3. 2 Muni Fund Picks That Sidestep Market Turbulence

    Fidelity Municipal Income and T. Rowe Price Tax-Free High Yield hold up well when muni markets head south.

  4. “You’re Going to Need a Bigger Boat”: Alpha and Interest Rates

    All investments involve risk, including possible loss of principal. The value of investments can go down as well as up, and investors may not get back the full amount invested. The information provided in this posting is not a complete analysis of every material fact regarding any country, region, ...

  5. “You’re Going to Need a Bigger Boat”: Alpha and Interest Rates

    All investments involve risk, including possible loss of principal. The value of investments can go down as well as up, and investors may not get back the full amount invested. The information provided in this posting is not a complete analysis of every material fact regarding any country, region, ...

  6. Schneider: Volatility Will Be a Primary Focus for Investors

    As Fed policy tightens over the short term, investors will have to actively manage interest rate exposure while looking ahead to a 'new neutral' in the next three to five years, says PIMCO's Jerome Schneider.

  7. Putnam Announces Dividend Rates for Class a Open-End Funds

    Putnam Announces Dividend Rates for Class a Open-End Funds

  8. ETFs take center stage at Morningstar conference

    ETFs take center stage at Morningstar conference

  9. Detailed Results from Biogen Idec and AbbVie’s Pivotal Phase 3 Decide Study Further Define the Efficacy and Safety Profile of ZINBRYTA™ (Daclizumab High -Yield Process)

    Detailed Results from Biogen Idec and AbbVie’s Pivotal Phase 3 Decide Study Further Define the Efficacy and Safety Profile of ZINBRYTA™ (Daclizumab High - Yield Process)

12345
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.